Back to Search Start Over

503PActivity of afatinib in patients (pts) with NSCLC harboring uncommon EGFR mutations: Pooled analysis of three large phase IIIB trials.

Authors :
Passaro, A
Marinis, F De
Tu, H
Laktionov, K K
Feng, J
Poltoratskiy, A
Zhao, J
Tan, E-H
Gottfried, M
Lee, V
Kowalski, D
Yang, C-T
Srinivasa, B
Clementi, L
Tang, W
Huang, D C-L
Cseh, A
Park, K
Zhou, C
Wu, Y-L
Source :
Annals of Oncology. 2019 Supplement, Vol. 30, pN.PAG-N.PAG. 1p.
Publication Year :
2019

Abstract

Background In the registrational trials, afatinib (afa) was active against NSCLC tumors harboring common and uncommon EGFR mutations, including G719X, L861Q and S768I,1 and is approved in this setting. Here, we assess 1st-line afa in pts with uncommon EGFR mutations treated in a 'real-world' setting in the largest analysis of its kind to date. Methods Retrospective pooled analysis of three 'real-world' studies: an expanded-access program in Korea (1200.193); an Asian phase IIIB trial (1200.66); a global phase IIIB trial (mainly Europe; 1200.55). Pts had EGFR mutation-positive (EGFRm+) NSCLC, were EGFR TKI-naïve, and received afa 40 mg/day. Dose reduction was permitted (minimum 20 mg/day). Endpoints included time to symptomatic progression (TTSP), investigator-assessed PFS and ORR. Results Overall, 1108 pts were treated with afa: median age, 61 yrs; female, 58%; ECOG PS of 0/1/2, 26%/70%/4%; asymptomatic brain metastases, 19%; 1st-line afatinib, 69%. 198 (18%) had tumors harboring at least one uncommon mutation (exon 20 insertions [Ins20]: n = 70; T790M: n = 20; G719X: n = 41; L861Q: n = 47; S768I: n = 20; other: n = 25. Of note, 35% of pts had Ins20 mutations, a heterogeneous group generally resistant to EGFR TKIs). Median TTSP, PFS and ORR were 8.3 mos (95% CI 7.2–11.0), 7.4 mos (95% CI 6.0–9.0) and 37% respectively. Median duration of response was 10.2 mos (95% CI 8.4–12.9). In those pts with uncommon mutations and brain metastases, median TTSP and PFS were 7.6 mos (95% CI 4.6–10.1) and 7.4 mos (95% CI 4.6–9.1). Clinical activity in pts with uncommon mutations was greatest against tumors harboring G719X, L861Q or S768I. Some pts with Ins20 or T790M mutations appeared to benefit from treatment. Survival data in specific mutation subgroups will be presented. Conclusions In this 'real-world' analysis, nearly 20% of pts with EGFRm+ NSCLC harbored uncommon EGFR mutations. Afa was active in a broad range of these pts, including some with Ins20 mutations. 1. Yang, JC. et al. Lancet Oncol 2015;16:830–8. Table: 503P   EGFR mutation type   Common   Uncommon   Del19  L858R  T790M  Ins20  T790M + Ins 20  G719X, L861Q, S768I and Other  n  531  378  15  65  5  113  Median TTSP, mos (95% CI)  17.2 (15.5, 19.3)  14.5 (13.1, 16.5)  8.2 (2.7, 13.4)  5.9 (3.8, 8.2)  1.5 (0.1, 13.0)  11.0 (9.0, 16.4)  Median PFS, mos (95% CI)  14.5 (13.8, 15.9)  12.6 (11.1, 13.8)  7.1 (2.0, 9.0)  5.6 (3.9, 7.4)  1.5 (0.1, 9.1)  9.2 (7.3, 12.1)  ORR, %  64  52  20  23  20  49  Median DOR, mos (95% CI)  14.1 (12.6, 16.2)  12.5 (11.1, 14.9)  12.5 (1.1, 12.5)  10.1 (3.7, 21.2)  8.3 (NE, NE)  10.2 (8.3, 15.5)    EGFR mutation type   Common   Uncommon   Del19  L858R  T790M  Ins20  T790M + Ins 20  G719X, L861Q, S768I and Other  n  531  378  15  65  5  113  Median TTSP, mos (95% CI)  17.2 (15.5, 19.3)  14.5 (13.1, 16.5)  8.2 (2.7, 13.4)  5.9 (3.8, 8.2)  1.5 (0.1, 13.0)  11.0 (9.0, 16.4)  Median PFS, mos (95% CI)  14.5 (13.8, 15.9)  12.6 (11.1, 13.8)  7.1 (2.0, 9.0)  5.6 (3.9, 7.4)  1.5 (0.1, 9.1)  9.2 (7.3, 12.1)  ORR, %  64  52  20  23  20  49  Median DOR, mos (95% CI)  14.1 (12.6, 16.2)  12.5 (11.1, 14.9)  12.5 (1.1, 12.5)  10.1 (3.7, 21.2)  8.3 (NE, NE)  10.2 (8.3, 15.5)  Table: 503P   EGFR mutation type   Common   Uncommon   Del19  L858R  T790M  Ins20  T790M + Ins 20  G719X, L861Q, S768I and Other  n  531  378  15  65  5  113  Median TTSP, mos (95% CI)  17.2 (15.5, 19.3)  14.5 (13.1, 16.5)  8.2 (2.7, 13.4)  5.9 (3.8, 8.2)  1.5 (0.1, 13.0)  11.0 (9.0, 16.4)  Median PFS, mos (95% CI)  14.5 (13.8, 15.9)  12.6 (11.1, 13.8)  7.1 (2.0, 9.0)  5.6 (3.9, 7.4)  1.5 (0.1, 9.1)  9.2 (7.3, 12.1)  ORR, %  64  52  20  23  20  49  Median DOR, mos (95% CI)  14.1 (12.6, 16.2)  12.5 (11.1, 14.9)  12.5 (1.1, 12.5)  10.1 (3.7, 21.2)  8.3 (NE, NE)  10.2 (8.3, 15.5)    EGFR mutation type   Common   Uncommon   Del19  L858R  T790M  Ins20  T790M + Ins 20  G719X, L861Q, S768I and Other  n  531  378  15  65  5  113  Median TTSP, mos (95% CI)  17.2 (15.5, 19.3)  14.5 (13.1, 16.5)  8.2 (2.7, 13.4)  5.9 (3.8, 8.2)  1.5 (0.1, 13.0)  11.0 (9.0, 16.4)  Median PFS, mos (95% CI)  14.5 (13.8, 15.9)  12.6 (11.1, 13.8)  7.1 (2.0, 9.0)  5.6 (3.9, 7.4)  1.5 (0.1, 9.1)  9.2 (7.3, 12.1)  ORR, %  64  52  20  23  20  49  Median DOR, mos (95% CI)  14.1 (12.6, 16.2)  12.5 (11.1, 14.9)  12.5 (1.1, 12.5)  10.1 (3.7, 21.2)  8.3 (NE, NE)  10.2 (8.3, 15.5)  Clinical trial identification NCT01931306; NCT01953913; NCT01853826. Editorial acknowledgement Lynn Pritchard of GeoMed, an Ashfield company, part of UDG Healthcare plc. Legal entity responsible for the study Boehringer Ingelheim. Funding Boehringer Ingelheim. Disclosure F. De Marinis: Honoraria (self): Roche; Honoraria (self): AstraZeneca; Advisory / Consultancy: Takeda; Research grant / Funding (institution): Boehringer Ingelheim. V. Lee: Honoraria (self), Advisory / Consultancy: Pfizer; Honoraria (self): Eli Lilly; Honoraria (self), Advisory / Consultancy: Roche; Honoraria (self), Advisory / Consultancy: AstraZeneca; Honoraria (self), Advisory / Consultancy: Merck Sharp & Dohme. L. Clementi: Full / Part-time employment: Boehringer Ingelheim. W. Tang: Full / Part-time employment: Boehringer Ingelheim. D.C-L. Huang: Full / Part-time employment: Boehringer Ingelheim. A. Cseh: Full / Part-time employment: Boehringer Ingelheim. K. Park: Advisory / Consultancy: AMGEN; Advisory / Consultancy: Astellas; Advisory / Consultancy, Speaker Bureau / Expert testimony, Research grant / Funding (self): AstraZeneca; Advisory / Consultancy: BluePrint; Advisory / Consultancy: BMS; Advisory / Consultancy, Speaker Bureau / Expert testimony: Boehringer Ingelheim; Advisory / Consultancy: Eli Lilly; Advisory / Consultancy: Hanmi; Advisory / Consultancy: KHK; Advisory / Consultancy: Loxo; Advisory / Consultancy: Merch KGaA; Advisory / Consultancy, Research grant / Funding (self): MSD; Advisory / Consultancy: ONO; Advisory / Consultancy: Roche. C. Zhou: Honoraria (self): BI; Honoraria (self): Roche; Honoraria (self): Sanofi; Honoraria (self): Hengrui; Honoraria (self): Qilu; Honoraria (self): MSD. Y-L. Wu: Honoraria (self), Advisory / Consultancy, Research grant / Funding (institution): AstraZeneca; Honoraria (self): Roche; Honoraria (self), Advisory / Consultancy, Research grant / Funding (institution): Boehringer Ingelheim; Honoraria (self): Pfizer; Honoraria (self): Eli Lilly; Honoraria (self): MDS; Honoraria (self): BMS. All other authors have declared no conflicts of interest. [ABSTRACT FROM AUTHOR]

Details

Language :
English
ISSN :
09237534
Volume :
30
Database :
Academic Search Index
Journal :
Annals of Oncology
Publication Type :
Academic Journal
Accession number :
140828704
Full Text :
https://doi.org/10.1093/annonc/mdz437.029